看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.8x - 2.0x | 1.9x |
| Historical Pb Multiple | 1.8x - 2.3x | 1.9x |
| Fair Value | ¥3.77 - ¥4.16 | ¥3.96 |
| Upside | -0.6% - 9.8% | 4.6% |
| Benchmarks | - | Full Ticker |
| Hainan Shuangcheng Pharmaceuticals Co., Ltd. | 269,300.0% | SZSE:002693 |
| Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. | 68,807,600.0% | SHSE:688076 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 60,019,600.0% | SHSE:600196 |
| Jiangsu Hengrui Medicine Co., Ltd. | 60,027,600.0% | SHSE:600276 |
| Livzon Pharmaceutical Group Inc. | 51,300.0% | SZSE:000513 |
| Harbin Pharmaceutical Group Co., Ltd. | 60,066,400.0% | SHSE:600664 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| 2693 | 688076 | 600196 | 600276 | 513 | 600664 | |||
| SZSE:002693 | SHSE:688076 | SHSE:600196 | SHSE:600276 | SZSE:000513 | SHSE:600664 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 52.5% | -3.6% | 3.5% | 9.6% | 2.7% | ||
| 3Y CAGR | NM- | 51.4% | -16.3% | 11.8% | 5.1% | NM- | ||
| Latest Twelve Months | -889.7% | 145.9% | -40.9% | 47.3% | 5.5% | 2.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -16.5% | 18.4% | 10.7% | 20.0% | 17.2% | 0.8% | ||
| Prior Fiscal Year | 3.3% | 15.8% | 5.8% | 18.9% | 15.7% | 3.4% | ||
| Latest Fiscal Year | -21.5% | 24.7% | 6.8% | 22.6% | 17.4% | 2.6% | ||
| Latest Twelve Months | -48.1% | 24.7% | 6.8% | 22.6% | 17.4% | 3.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -3.9% | 9.9% | 9.5% | 15.5% | 14.3% | 2.4% | ||
| Prior Fiscal Year | 1.8% | 8.0% | 8.9% | 11.0% | 14.0% | 11.4% | ||
| Latest Twelve Months | -18.1% | 16.7% | 4.5% | 14.7% | 14.8% | 12.5% | ||
| Next Fiscal Year | -13.6% | 19.7% | 7.3% | 14.6% | 15.6% | 10.5% | ||
| Two Fiscal Years Forward | -16.1% | 21.9% | 8.3% | 14.1% | 17.5% | 9.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 19.7x | 8.0x | 1.4x | 11.2x | 2.5x | 0.6x | ||
| Price / LTM EPS | -40.9x | 32.3x | 28.4x | 49.4x | 14.2x | 15.0x | ||
| Price / Book | 8.2x | 5.0x | 1.3x | 6.9x | 2.1x | 1.8x | ||
| Price / Fwd Book | 8.9x | 4.4x | 1.5x | 6.4x | 2.1x | 1.8x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.3x | 5.0x | 8.2x | |||||
| Historical P/B Ratio | 1.8x | 1.9x | 2.3x | |||||
| Selected P/B Multiple | 1.8x | 1.9x | 2.0x | |||||
| (x) Book Value | 5,212 | 5,212 | 5,212 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 2693 | 688076 | 600196 | 600276 | 513 | 600664 | |
| Value of Common Equity | 3,600 | 13,369 | 68,421 | 329,373 | 28,857 | 9,545 | |
| (/) Shares Outstanding | 414.7 | 219.8 | 2,657.1 | 6,358.6 | 792.3 | 2,518.5 | |
| Implied Stock Price | 8.68 | 60.83 | 25.75 | 51.80 | 36.42 | 3.79 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8.68 | 60.83 | 25.75 | 51.80 | 36.42 | 3.79 | |
| Trading Currency | CNY | CNY | CNY | CNY | CNY | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |